Business Context and Reporting Period
This Form 8-K Current Report was filed by Nephros, Inc. on February 5, 2013, covering events occurring on February 4, 2013. The company, incorporated in Delaware, is engaged in the development of water filtration and chronic renal failure therapy products. The filing primarily addresses a new debt financing arrangement and a planned equity rights offering intended to fund operations.
Key Financial Metrics and Obligations
- Debt Financing: Issued a senior secured note to Lambda Investors LLC with a principal amount of $1.3 million.
- Interest Rate: 12% per annum, increasing to 16% per annum upon default.
- Maturity Date: August 4, 2013.
- Transaction Costs: Agreed to pay an 8% sourcing/transaction fee ($104,000) plus $50,000 in legal fees for the note and $50,000 in legal fees for the associated rights offering.
- Liquidity Outlook: Proceeds from the note are expected to fund operations through May 2013.
- Planned Equity Raise: Undertaken to conduct a $3 million rights offering of common stock at an expected price of $0.60 per share.
Material Changes and Agreements
The company entered into a material definitive agreement creating a direct financial obligation. The $1.3 million note is secured by a first-priority lien on all company property, including intellectual property. The agreement includes strict covenants restricting the company's ability to merge, sell material assets, incur additional indebtedness, or pay dividends while the note is outstanding. Additionally, the company agreed to prepay the note using proceeds from the planned rights offering, other financing, or asset sales.
As part of the transaction, the company agreed to amend the terms of warrants held by Lambda Investors (the largest stockholder, owning approximately 31.2% of outstanding stock and 53% on a fully-diluted basis) to extend their maturity to March 10, 2017. Lambda Investors waived anti-dilution rights regarding a one-time discounted exercise price offer to public warrantholders.
Guidance, Risks, and Contingencies
Outlook: The company expects to commence the $3 million rights offering in March 2013 following the filing of its Annual Report on Form 10-K. The offering is contingent on the effectiveness of a registration statement on Form S-1.
Risks and Contingencies:
- Going Concern: The filing explicitly states the company may not be able to continue as a going concern.
- Default Risk: A default on the secured note could result in the lender foreclosing on substantially all assets, halting business operations.
- Financing Failure: Failure to complete the rights offering could result in an inability to continue operations.
- Capital Sufficiency: Even if the offering is completed, capital may be insufficient to implement the business plan.
- Operational Restrictions: Covenants in the note may restrict business operations, asset sales, or mergers without lender consent.
Investor Verification Checklist
- Verify the effectiveness of the Form S-1 registration statement for the $3 million rights offering.
- Confirm the company's cash runway and ability to meet the August 4, 2013, maturity date of the $1.3 million note.
- Review the impact of the 12% interest rate and $204,000 in immediate transaction fees on future cash flow.
- Assess the dilution impact of the rights offering and the discounted warrant exercise price for public holders.
- Monitor the company's ability to comply with restrictive covenants preventing additional debt or asset sales.